Compare Amazon.com Inc (AMZN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Gilead Sciences, Inc. — how do they compare? Amazon.com Inc trades at $244.98 (market cap $2.64T), while Gilead Sciences, Inc. trades at $130.34 (market cap $161.19B). The key difference: Amazon.com Inc is far larger — about 16.4× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.53% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | GILD | |
|---|---|---|
Market Cap | $2.64T | $161.19B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $155.80 |
52-Week Low | $198.79 | $108.22 |
Enterprise Value | $2.71T | $175.72B |
Dividend Yield | — | 2.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Recent CEO communications highlight Amazon's AI chip business reaching $20+ billion run-rate and strong visibility into future cash flows from massive capital investments.
Amazon presents a compelling investment case with 88% analyst buy ratings and a $320.75 consensus price target representing 31% upside. Key opportunities include AWS growth and AI leadership, while risks involve intense retail competition and the sustainability of massive capital expenditures. The stock's current valuation at 29.35 P/E appears reasonable given growth trajectory and profitability improvements.
Gilead Sciences (GILD) trades at $129.83, down 3.72% on the day, with a bullish technical signal and strong fundamentals including a 30.99% net income margin and 43.19% ROE. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer expand its oncology portfolio, while earnings have consistently beaten estimates in recent quarters. The stock shows robust profitability and cash flow generation despite a net cash outflow in 2025.
Outlook remains positive with a consensus price target of $154.57 (19% upside), supported by analyst bullishness (67% buy ratings) and growth catalysts in HIV and oncology. Key risks include patent expirations for key drugs and competitive pressures in the biotech sector. The valuation at 17.66x P/E appears reasonable given earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
